Formycon AG’s Strategic Partnerships and Biosimilar Advancements Drive Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Yi Chen reiterated a Buy rating for Formycon AG, setting a €40.00 price target, citing strategic partnerships and biosimilar advancements. Key developments include a licensing deal with MS Pharma for FYB206 in the MENA region and collaboration with NTC s.r.l. for FYB203 in Italy. These moves, along with the technical proof of similarity for FYB208, support a positive outlook. Berenberg Bank also maintained a Buy rating with a €30.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments